FDA Clearance Isn’t Enough: The Reimbursement Moat for Cardiac AI Wins

The healthcare AI investment landscape is often characterized by a singular focus on regulatory milestones, particularly FDA clearance. While undeniably critical for market entry, this narrow lens frequently overlooks a more profound determinant of commercial success and, ultimately, investor returns: the intricate and often elusive path to reimbursement. A 510(k) clearance or even a De Novo classification is merely a ticket to the game; securing consistent, scalable reimbursement is what allows a company to play, and thrive.

The Regulatory Hurdle vs. The Reimbursement Moat

The journey from innovative AI algorithm to commercially viable medical device is fraught with challenges, and regulatory approval is just the first significant checkpoint. For Software as a Medical Device (SaMD), the FDA has established a clear framework, outlining pathways like 510(k) clearance for devices substantially equivalent to a predicate, or De Novo classification for novel, low-to-moderate-risk devices without a predicate. This framework provides a predictable, albeit rigorous, process for establishing safety and effectiveness. However, achieving FDA clearance does not automatically translate into a clear path to revenue. Consider the divergent fortunes and strategic approaches of companies like Anumana, AliveCor, HeartFlow, and iRhythm. Each has navigated the regulatory landscape with varying degrees of success, yet their commercial trajectories are far more closely tied to their ability to secure and scale reimbursement. Anumana, for instance, spun from the Mayo Clinic, has strategically focused on demonstrating robust clinical utility to underpin its reimbursement strategy. The company’s efforts to secure CPT codes for its ECG-AI are a testament to this foresight, aiming to establish a “reimbursement moat” that provides a significant competitive advantage. Anumana received Category III CPT codes (0764T and 0765T) in 2023, and its low ejection fraction (LEF) ECG-AI technology was included in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule by CMS, effective January 1, 2025, allowing for reimbursement in outpatient settings. The company also secured FDA 510(k) clearance for ECG-AI LEF in October 2023. AMA CPT code application process In contrast, other companies, even those with strong regulatory showings, have faced significant headwinds. The story of HeartFlow, funded by Bain Capital and having successfully completed an IPO on Nasdaq, illustrates this point vividly. Despite securing regulatory clearances for its CT-FFR technology, the path to widespread, stable reimbursement has been a continuous battle. However, HeartFlow FFRCT Analysis now has an established reimbursement pathway with a Category I CPT code as of January 1, 2024, covered for 99.5% of lives in the U.S. with health insurance. Additionally, HeartFlow Plaque Analysis received a favorable coverage decision by Medicare Administrative Contractors and a Category I CPT code (75577) effective January 1, 2026, and is covered by major commercial insurers. Without established CPT codes or consistent payer coverage, even groundbreaking technology struggles to achieve broad adoption and generate predictable revenue streams.

Beyond Clearance: The Payer Penetration Imperative

For investors, the evaluation criteria must extend well beyond the FDA’s green light. Our framework emphasizes clinical validation score, regulatory risk rating, payer penetration depth, and published outcomes data precisely because these metrics collectively paint a more accurate picture of a company’s commercial viability. A high regulatory risk rating might stem from an unclear predicate device or an adaptive AI/ML model lacking a Predetermined Change Control Plan (PCCP), but even a low regulatory risk doesn’t guarantee success if payer penetration is shallow. AliveCor, with its personal ECG devices, has achieved significant regulatory milestones. The company’s Kardia 12L ECG System received Category III CPT codes in July 2024, effective January 1, 2025. Furthermore, CMS included AliveCor’s AI-powered ECG technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule, assigning it to APC 5733 with a Medicare payment rate of $59.40, effective January 1, 2025. The commercial success of such devices hinges on whether they are covered by commercial payers and Medicare, and under what circumstances. The sheer volume of data generated by such devices can also contribute to a “data moat,” making it harder for competitors to match their performance over time due to the difficulty in replicating such extensive, real-world datasets. However, a data moat alone doesn’t pay the bills; robust outcomes data demonstrating cost savings or improved patient outcomes are often prerequisites for favorable reimbursement decisions. iRhythm, a pioneer in long-term cardiac monitoring with its Zio XT patch, provides an instructive case study in building a successful reimbursement strategy. They meticulously gathered Real-World Evidence (RWE) to demonstrate the clinical utility and economic value of their solution. This extensive outcomes data, coupled with strategic engagement with payers, allowed them to secure favorable coverage policies, which in turn fueled their growth and cemented their market leadership. This dedication to building a strong economic value proposition, supported by clinical evidence, is a critical differentiator.

The FDA SaMD Framework: A Necessary, But Insufficient, Condition

The FDA’s SaMD Framework provides a robust regulatory pathway for AI-powered medical devices, classifying them based on the significance of the information provided by the SaMD and the state of the healthcare situation or condition. This framework guides developers in understanding the appropriate regulatory controls and evidence requirements. For instance, a diagnostic AI that provides information to treat or diagnose a critical condition (e.g., detecting a life-threatening arrhythmia) would be subject to higher regulatory scrutiny than a clinical decision support tool that merely offers recommendations. However, the FDA’s purview is primarily safety and efficacy, not economic value or reimbursement. While clinical validation is a core component of FDA clearance, the level of evidence required for regulatory approval often differs from that demanded by payers. Payers typically seek evidence of improved patient outcomes, reduced healthcare costs, or enhanced efficiency, all of which contribute to a clear return on investment. This means that companies cannot simply rest on their FDA clearance; they must continue to invest in generating robust outcomes data that resonates with payer priorities. CMS guidance on new technology payment

The Investment Implication: Prioritizing Payer Strategy

For VCs and growth equity investors evaluating healthcare AI companies, the key takeaway is clear: FDA clearance is a foundational requirement, but it is not a predictor of investment returns. The true differentiator lies in a company’s ability to navigate the complex reimbursement landscape. This means scrutinizing a company’s payer penetration depth, the existence and stability of its CPT codes, and the quality and quantity of its published outcomes data. Companies that prioritize a proactive and well-resourced reimbursement strategy from inception, much like Anumana’s focus on CPT codes or iRhythm’s extensive RWE generation, are far better positioned for long-term commercial success. Those that view reimbursement as an afterthought, or solely rely on the clinical merit validated by the FDA, risk becoming “zombie companies”, technologically advanced but commercially constrained. An investment thesis for healthcare AI must therefore be built on a comprehensive understanding of both regulatory compliance and, crucially, the “reimbursement moat” that separates market leaders from also-rans. AHIP payer coverage policy best practices